anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a composite preparation for treating osteoporosis, which belongs to the technical field of oral preparations. The composite preparation is made from the following raw materials in part by weight: 5 to 50 parts of safflower, 30 to 120 parts of pseudo-ginseng root, 6 to 60 parts of astragalus, 10 to 100 parts of ginseng, 10 to 80 parts of bark of eucommia and 5 to 50 parts of dried tangerine. The preparation can be formed into the following formulations: capsules, patches, granules, spray, tablets, pills, mixture and the like. The product has the effects of improving blood circulation and micro circulation, tonifying liver and kidney, activating blood and tonifying qi. According to treatment based on syndrome differentiation, the bark of eucommia is mainly used for tonifying kidney and yin, strengthening bone and promoting marrow growth; the ginseng and the astragalus are used for tonifying qi, blood and spleen; the pseudo-ginseng root and safflower are used for activating blood; and the dried tangerine is used for unblocking collaterals. The medicines are used in combination to regulate the yin and yang balance in human body, promote marrow growth and strengthen bone. The results of pharmacodynamic and clinic tests indicate the product invented has remarkable treatment effect on osteoporosis and is safe and reliable when used continuously.
Post-operative cystoid macular edema (PCME) is an important complication following intraocular surgery that often resolves spontaneously without treatment. In some cases, PCME may persist despite initial medical therapy, which can adversely impact visual outcomes. Various topical, intraocular and systemic treatments exist for the prevention and management of cystoid macular edema; however, there is no consensus on treatment of refractory cases in the postoperative setting. In accordance with the PRISMA guidelines, we systematically reviewed 68 articles describing management options and their outcomes for treatment-resistant cases of PCME. The most commonly reported treatments included steroid (39 studies) and biological-based (17 studies) therapies. We provide an overview of the treatment options for refractory PCME.
A single patch of currently marketed EVRA patch using the adhesive component at the beginning of shelf life (BOSL) (Treatment A) will be applied to the right buttock of participants on Day 1 of Treatment Period 1, followed by application of a single patch of transdermal contraceptive using newly sourced adhesive component HMW PIB at the end of shelf life (EOSL) (Treatment B) to left buttock of participants on Day 1 of Treatment Period 2. The Treatment periods will be separated by a washout period of 21 days.
MORPH participants will attend one weekly group-mediated session alongside a group of their peers plus individual coaching calls. Participants will aim to increase daily steps by moving often throughout the day, using an activity monitor and mHealth app to view feedback and set goals. Participants will also aim to weight via healthy eating while reducing daily calories by \~400kcal/day below weight maintenance needs to achieve approximately 6% weight loss in 6 months and 10% over 18 months.
The present invention provides a Dendropanax morbifera Lev. fractionate having activities on PPAR α, γ, and σ, the fractionate being characterized by: (1) preparing an extract of Dendropanax morbifera Lev. leafs by introducingDendropanax morbifera Lev. leafs into water-containing alcohol; (2) cooling the Dendropanax morbifera Lev. leaf extract to 20-50°C followed by filtration and then separating supernatant of the filtrated solution thus obtained to obtain a concentrate using a rotary evaporator; (3) extracting the concentrate obtained in step (2) for 24 hours at the room temperature using any one or more selected from hexane, chloroform, ethyl acetate, butanol, and water ; (4) taking supernatant by filtering the extract obtained in step (3) through a filter and then removing hexane by decompressing the supernatant through a rotary evaporator to fractionate the Dendropanax morbifera Lev. extract; and (5) measuring presence and absence of an activity of the resultant fractionate on PPAR α, γ, and σ.
Disclosed are a medical information analysis service system, which can provide a service to any third parties by analyzing medical information collected by an information generation device through IoT, and a medical information analysis service method using the same. The medical information analysis service system includes a blockchain system and a medical information analysis service server. The blockchain system includes a plurality of nodes that store a plurality of pieces of medical information generated, respectively, by a plurality of information generation devices disposed on a plurality of people, respectively. The medical information analysis service server may receive the medical information from at least one node of the nodes, analyze the received medical information to generate a medical information service, and provide the generated medical information service to at least one user terminal. The medical information includes biometric data measured from each of the people. Accordingly, the usability of the medical information may be further improved by providing the medical information service to a terminal of a third party, not an owner of the information generation device.
The current standard therapeutic strategy for RA patients is to initiate a DMARDs therapy, (e.g. MTX) with serious side effects. This also applies to some PSO or SNSA patients. MTX is however inefficient in about 40% of the cases. Other treatments (biological DMARDs) must thus be initiated, which have an overall similar effectiveness and side effects and an higher cost (around 13kEUR/year/patient). Therapeutic choices are based on symptoms and blood tests including markers of inflammation which are inadequate to predict disease evolution and response to treatments. Improving RA management requires to improve the adequacy of the therapeutic strategies. The earlier the disease is correctly addressed, the more likely its progression and irreversible damages to the joints will be limited. DNAlytics recently developed RheumaKit a differential diagnostic solution for UA patients. UA is a condition in which joint inflammation is present, but a precise diagnosis cannot be made, due to the lack of sensitivity of presently available diagnostic techniques. RheumaKit is a multi-gene expression solution that discriminates RA from other joint conditions. A diagnostic model train to identify patients suffering from RA, SNSA or OA. RheumaKit diagnostic accuracy is higher than 90%, a performance that is better than any other diagnostic solution designed until now, including the ACR/EULAR 2010 criteria for the diagnosis of RA. See working principle below. Beyond diagnosis, DNAlytics wants to make RheumaKit evolve towards treatment recommendation applications (theranostic applications) for patients eligible for biological DMARDs. On one hand, the diseases of these patients have been more and more described in terms of the activity of several metabolic pathways (T \& B cells activation, Extra cellular matrix, Inteferon, TNF). On the other hand, the existing treatments also have been more and more described in terms of the pathways they target. The RheumaKit signature contains many markers that are representative of these pathways of interest. RheumaKit thus now provides a snapshot of the activity of seven metabolic pathways known from literature to be related to diseases mechanisms, or to be target of existing treatments. In this study, DNAlytics wants to show that based on a score defined on the RheumaKit platform, the response or non- response to anti-TNFs, representing the largest category of biological DMARDs, can be predicted before treatment initiation.
The invention discloses a phenylethyl resorcinol hydroxypropyl-beta-cyclodextrin inclusion. The phenylethyl resorcinol hydroxypropyl-beta-cyclodextrin inclusion is characterized in that a carrier loaded is phenylethyl resorcinol. The phenylethyl resorcinol hydroxypropyl-beta-cyclodextrin inclusion has the effects of skin whitening, oxidization resisting and wrinkle resisting. A preparation method of the phenylethyl resorcinol is a vacuum drying method. The inclusion is prepared from phenylethyl resorcinol and hydroxypropyl-beta-cyclodextrin based on a molar ratio of 1: (1 to 100) by the optimized inclusion process. The inclusion is high in stability and water solubility. The preparation method is simple, controllable, and high in repeatability, and can be applied to the preparation of cosmetics containing the phenylethyl resorcinol.
The invention relates to a hand cleanser with a fragrant bag. The invention belongs to the technical field of articles for daily use. A paper tissue is packed inside the external package of the hand cleanser with the fragrant bag, and hand cleaner is contained in the paper tissue, and the hand cleanser with the fragrant bag is characterized in that a micro capsule which can emit scent is arranged on the paper tissue. Since concentrated feeding stuff is packed by the micro capsule, the concentrated feeding stuff of the hand cleanser just emit faint scent, and the micro fragrant bag is broken through the friction between the hand cleanser and a human body during the use process, the cleanser emits more scent when using a long time, and the scent is more durable after long time use. The hand cleanser has convenient use and durable scent, people can feel comfortable after use, and the hand cleanser is especially suitable for top-grade places and special crowded. The product can be produced into hand cleanser products with different types of scent in batch aiming at different people groups.
This study aims to assess the group-based cardiac telerehabilitation model and its effectiveness. The data is collected from two University hospitals in Finland. Patients with coronary heart disease two months after percutaneous coronary intervention (N=198) are invited to the study. All the participants are being treated in a healthcare unit that uses digital care pathways for coronary patients. Patients can choose the usual care or group-based cardiac telerehabilitation as follow-up care. All the patients are invited to the study after the chosen follow-up care (telerehabilitation or usual care). Patients will be allocated into two groups: The telerehabilitation group is the intervention group and the usual care group is the control group. Quality of life, adherence to treatment, and lifestyle changes are measured at the baseline and 3, 6, and 12 after the intervention baseline.
Multiple myeloma is a plasma cell neoplasm with median survival of 3 to 5 years. Recent advances have improved patient outlook, but the disease remains incurable and patients become refractory to treatments, develop organ dysfunction from myeloma itself, and encounter severe toxicities from therapies, limiting further treatment options. Subjects over the age of 18 with relapsed or refractory multiple myeloma who have had at least one prior therapy, have a life expectancy of at least 4 weeks and an ECOG performance status of 0,1 or 2 will be included. The investigators propose an initial pilot trial to test the feasibility of giving standard chemotherapy with infusional cyclophosphamide and pulse dexamethasone (cy/dex) for four days, together with the investigational agents, oral rapamycin (cohort A), and in a separate parallel arm, oral hydroxychloroquine (HCQ) (cohort B). The investigators will enroll 3 patients on cohort A and 3 patients on cohort B, both at the planned 1st dose level for the overall phase I/II trial which will succeed this trial if feasibility is demonstrated. The 6 patients from this pilot trial will be included in total number of patients for the overall study which will be completed when further funding is secured. Feasibility will be defined by the ability to deliver the regimen as planned and the ability to perform the planned correlative studies. Subjects will receive up to 12 cycles and will be followed for 12 months after the last cycle. Data collected will include toxicity, response rates, correlative studies to examine the pharmacodynamics of mTOR inhibition and autophagy and the pharmacokinetics of rapamycin and HCQ.
PROBLEM TO BE SOLVED: To obtain the subject compound having good oral absorbability, exhibiting antagonistic actions against substane P and neurokinin A receptor, and useful as a medicine for preventing and treating tachykinin-intervening diseases. SOLUTION: A compound of formula I or II [R<1> , R<2> are each an aryl, a heterogeneous aryl, etc.; R<3> is a lower alkyl; A is methylene, carbonyl, sulfonyl; B is a single bond, a 1-4C alkylene, a 2-4C alkenylene: D is O atom, S atom; E is a (halogenated) 1-6C alkylene, etc.; G is a 1-4C alkylene, etc.; J is a 1-6C alkylene, ring Ar is an aryl, a heterogeneous aryl, etc.; the formula: S*→O is sulfoxide where the O atom is bound to the S atom in an S configuration]. The compound of formula I or II is obtained e.g. by reacting a compound of formula III with a compound of formula IV (Y is a group capable of releasing as a nucleophilic residue) as starting raw materials.
This invention describes a novel format of monomeric bispecific fusion protein with immune activating property for clinical therapies. A bispecific fusion protein includes a first targeting domain with a specificity for a first target of interest; a bridging domain derived from a constant region of a light chain or heavy chain of an immunoglobulin, which may be a human immunoglobulin; and a second targeting domain with a specificity for a second target of interest. The bispecific fusion protein may further include a linker fused to the N-terminus or the C-terminus of the bridging domain. The first targeting domain is fused to the bridging domain and the second targeting domain is fused to the bridging domain or the linker. The linker may include a GGGGS sequence. The first target of interest may be CD20, Her2/neu, or EpCAM, and the second targeting domain is a T-lymphocyte activating domain.
The proposed project will examine the impact of a novel anticoagulant (AC) clinical decision support tool within the electronic health record (EHR) on AC prescribing behaviors among healthcare providers from two distinct health systems who receive it. Using a mixed-methods approach, the investigators will also examine how healthcare providers interact with the decision support tool to further refine the tool and measure its impact on anticoagulation prescribing behaviors. The investigators will also examine clinician engagement through provider interviews and detailed study of behaviors using electronic health record access logs. Finally, the investigators will refine the alert, develop a comprehensive dissemination plan, and create an implementation toolkit to widen the use of the alert at other learning health systems nationally.

After identifying a list of all cardiology providers and primary care providers (PCPs), the investigators will send an email to all providers notifying them of our research study and request for participation. The investigators will send this email through our data collection platform- Redcap-with a link to one item survey allowing providers to opt out. This follows the prior SUPPORT-AF II protocol which the investigators' Institutional Review Board (IRB) approved. Based on discussions with the IRB, the investigators do not anticipate requiring informed consent from providers or patients for executing this aim of the proposal. After removing providers who opted out, the investigators will randomize the remaining providers to either intervention or control in a 1:1 ratio, using randomly permuted blocks; randomization will be stratified jointly by provider type (cardiologist / PCP) and study site (University of Massachusetts/University of Florida). The allocation of the provider conducting the first visit for a patient will dictate the allocation for the patient.
BACKGROUND: Permanent pacemaker (PPM) implantation has been identified as a risk factor for morbidity and mortality after Fontan operation. This study investigated the factors associated with outcomes in patients with Fontan physiology who underwent PPM implantation.
METHODS AND RESULTS: We retrospectively reviewed 508 patients who underwent Fontan surgery at Asan Medical Center between September 1992 and August 2022. Of these patients, 37 (7.3%) received PPM implantation. Five patients were excluded, leaving 32 patients, of whom 11 were categorized into the poor outcome group. Poor outcomes comprised death, heart transplantation, and "Fontan failure". Clinical, Fontan procedure-related, and PPM-related factors were compared between the poor and good outcome groups. Ventricular morphology, Fontan procedure-associated factors, pacing mode, high ventricular pacing rate, and time from first arrhythmia to PPM implantation did not differ significantly between the 2 groups. However, the poor outcome group exhibited a significantly longer mean paced QRS duration (P=0.044). Receiver operating characteristic curve analysis revealed a paced QRS duration cut-off value of 153 ms with an area under the curve of 0.73 (P=0.035).
CONCLUSIONS: A longer paced QRS duration was associated with poor outcomes, indicating its potential to predict adverse outcomes among Fontan patients.
BACKGROUND: Rheumatoid arthritis (RA) is a chronic immune system disease with a high disability rate threatening the living quality of patients. Identifying potential biomarkers for RA is of necessity to improve the prevention and management of RA.
OBJECTIVES: This study focused on miR-146b-3p evaluating its clinical significance and revealing the underlying regulatory mechanisms.
MATERIALS AND METHODS: A total of 107 RA patients were enrolled, and both serum and synovial tissues were collected. Another 78 osteoarthritis patients (OA, providing synovial tissues), and 72 healthy individuals (providing serum samples) were enrolled as the control group. The expression of miR-146b-3p was analyzed by PCR and analyzed with ROC and Pearson correlation analyses evaluating its significance in diagnosis and development prediction of RA patients. In vitro, MH7A cells were treated with TNF-α. The regulation of cell proliferation, motility, and inflammation by miR-146b-3p was assessed by CCK8, Transwell, and ELISA assays.
RESULTS: Significant upregulation of miR-146b-3p was observed in serum and synovial tissues of RA patients, which distinguished RA patients and were positively correlated with the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), anti-cyclic citrullinated peptide antibodies (anti-CCP), and rheumatoid factor (RF) of RA patients. TNF-α promoted the proliferation and motility of MH7A cells and induced significant inflammation in cells. Silencing miR-146b-3p alleviated the effect of TNF-α and negatively regulated the expression of HMGCR. The knockdown of HMGCR reversed the protective effect of miR-146b-3p silencing on TNF-α-stimulated MH7A cells.
CONCLUSIONS: Increased miR-146b-3p served as a biomarker for the diagnosis and severity of RA. Silencing miR-146b-3p could suppress TNF-α-induced excessive proliferation, motility, and inflammation via regulating HMGCR in MH7A cells.
A method for correcting the impaired purine metabolism in the patients with arterial hypertension and metabolic syndrome comprises the biochemical examination of the blood serum for measuring the concentration of uric acid (UA). In the setting of the background antihypertensive therapy, hypouricemic drugs (HUDs) are prescribed. In addition, the blood concentrations of C-reactive protein (CRP) and vascular endothelial growth factor (VEGF) are measured. UA content is also determined in the urine. HUDs are prescribed differentially based on the detected type of the purine metabolism. In cases of the impaired purine metabolism associated with hyperuricemia when UA content is above the normal value only in blood serum, HUDs with uricodepressive activity is prescribed, for example Allopurinol at the prophylactic dose. In cases of the impaired purine metabolism associated with combined hyperuricemia and hyperuricosuria when UA content is above the normal value both in blood serum and in urine, the fixed low dose of the combined HUDs with uricodepressive and uricosuric activities is prescribed, for example Allomaron. When CRP concentration is increased at least by 15 % and VEGF concentration is increased at least by 25 %, the treatment is supplemented with the herbal anti-inflammatory drug such as Homvio-Reuman. HUDs are prescribed at the therapeutically effective and safe doses for 12 weeks. When the normalization of proinflammatory and proangiogenic factors is not sufficient, the treatment course for extra 6 weeks is provided.
Sepsis, characterized as a systemic inflammatory response triggered by the invasion of pathogens, represents a continuum that may escalate from mild systemic infection to severe sepsis, potentially resulting in septic shock and multiple organ dysfunction syndrome. Advancements in lipidomics and metabolomics have unveiled the complex role of fatty acid metabolism (FAM) in both healthy and pathological states. Leveraging bioinformatics, this investigation aimed to identify and substantiate potential FAM-related genes (FAMGs) implicated in sepsis. The approach encompassed a differential expression analysis across a pool of 36 candidate FAMGs. GSEA and GSVA were employed to assess the biological significance and pathways associated with these genes. Furthermore, Lasso regression and SVM-RFE methodologies were implemented to determine key hub genes and assess the diagnostic prowess of nine selected FAMGs in sepsis identification. The study also investigated the correlation between these hub FAMGs. Validation was conducted through expression-level analysis using the GSE13904 and GSE65682 datasets. The study identified 13 sepsis-associated FAMGs, including ABCD2, ACSL3, ACSM1, ACSS1, ACSS2, ACOX1, ALDH9A1, ACACA, ACACB, FASN, OLAH, PPT1, and ELOVL4. As demonstrated by functional enrichment analysis results, these genes played key roles in several critical biological pathways, such as the Peroxisome, PPAR signaling pathway, and Insulin signaling pathway, all of which are intricately linked to metabolic regulation and inflammatory responses. The diagnostic potential of these FAMGs was further highlighted. In short, the expression patterns of these FAMGs c effectively distinguished sepsis cases from non-septic controls, which suggested that they may be promising biomarkers for early sepsis detection. This discovery not only enhanced our understanding of the molecular mechanisms underpinning sepsis but also paved the way for developing novel diagnostic tools and therapeutic strategies targeting metabolic dysregulation in septic patients. This research sheds light on 13 FAMGs associated with sepsis, providing valuable insights into novel biomarkers for this condition and facilitating the monitoring of its progression. These findings underscore the significance of purine metabolism in sepsis pathogenesis and open avenues for further investigation into therapeutic targets.
RECOS(Cognitive Remediation for Schizophrenia) exercises were designed by SBT Company and adapted by Vianin et al (2007) for specific use in schizophrenia. It includes computer based and paper and pencil exercises that target 5 main cognitive functions. RECOS modules focus on the relevant cognitive domains, which have been recommended by the MATRICS consensus. Each exercise has 10 difficulty levels. Allocation of the training modules in RECOS was determined according to the standard scores obtained in the comprehensive neuropsychological assessment. Each patient participated in the module corresponding to his/her most altered cognitive area.